<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026230</url>
  </required_header>
  <id_info>
    <org_study_id>2016-004774-17</org_study_id>
    <nct_id>NCT04026230</nct_id>
  </id_info>
  <brief_title>Impact of Atorvastatin on Prostate Cancer Progression During ADT</brief_title>
  <acronym>ESTO2</acronym>
  <official_title>Impact of Atorvastatin on Prostate Cancer Progression After Initiation of Androgen Deprivation Therapy - Lipid Metabolism as a Novel Biomarker to Predict Prostate Cancer Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Finland Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fimlab laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized double-blind placebo-controlled trial tests whether intervention with&#xD;
      atorvastatin delays development of castration resistance compared to placebo during androgen&#xD;
      deprivation therapy (ADT) for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholesterol-lowering statin drugs have been reported to lower proliferation activity in&#xD;
      prostate cancer, delay occurrence of castration resistance and reduce the risk of prostate&#xD;
      cancer death. Therefore, it is important to test statins' efficacy in addition to&#xD;
      conventional prostate cancer treatment in a randomized, placebo-controlled trial.&#xD;
&#xD;
      This phase 3 randomized double-blind placebo-controlled trial will explore whether&#xD;
      intervention with atorvastatin delays prostate cancer progression i.e. development of&#xD;
      castration resistance compared to placebo during androgen deprivation therapy (ADT) for&#xD;
      metastatic or recurrent prostate cancer.&#xD;
&#xD;
      Secondary objectives include exploring whether atorvastatin lowers prostate cancer-specific&#xD;
      or overall mortality compared to placebo, and to demonstrate whether changes in serum lipid&#xD;
      parameters predict disease recurrence and occurrence of adverse genomic changes predicting&#xD;
      castration resistance among prostate cancer patients during ADT.&#xD;
&#xD;
      The study recruitment target is 400 participants who start ADT as management of metastatic or&#xD;
      recurrent prostate cancer. These men will be randomized 1:1 (200 + 200) to receive blinded&#xD;
      study drug, either 80 mg of atorvastatin daily or placebo until disease recurrence i.e.&#xD;
      development of castration resistance or for a maximum of five years.&#xD;
&#xD;
      The study will be carried out in collaboration between urological departments of University&#xD;
      Hospitals in Finland as a project of the national FinnProstata study group, Herlev University&#xD;
      Hospital in Denmark and the Tartu University Hospital in Estonia.&#xD;
&#xD;
      Follow-up is continued until the primary end-point, development of castration resistance.&#xD;
      After this the participants will be given the opportunity to voluntarily carry on with the&#xD;
      blinded intervention for maximum time of five year to observe effects on survival after&#xD;
      development of castration resistance. Blinding will be lifted after the follow-up is complete&#xD;
      for all study participants.&#xD;
&#xD;
      Castration resistance is defined as prostate-specific antigen (PSA) progression (three&#xD;
      consecutive rises of PSA measured at least 1 week apart with two &gt; 50% increases over the&#xD;
      nadir and PSA &gt; 2 ng/ml) or radiological disease progression (appearance of two or more&#xD;
      lesions in bone scan or soft tissue enlargement as per RECIST criteria) with serum&#xD;
      testosterone at castrate level (&lt; 1.73 nmol/l; 50 ng/dl) during ADT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Castration resistance</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance, assessed up to 60 months</time_frame>
    <description>Castration resistance is defined as PSA progression (three consecutive PSA rises measured at least 1 week apart with two &gt; 50% increases over the nadir and PSA &gt; 2 ng/ml) or radiological disease progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST criteria) with serum testosterone at castrate level (&lt; 1.73 nmol/l; 50 ng/dl) during ADT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months</time_frame>
    <description>Change in serum lipid levels during the intervention. Measured at baseline and in every follow-up visit. Results are blinded from the investigators and participants before the final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer mortality</measure>
    <time_frame>From date of randomization until the date of prostate cancer death, assessed up to 60 months</time_frame>
    <description>Followed through Finnish national registries after reaching the primary end-point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death due to any cause, assessed up to 60 months</time_frame>
    <description>Followed through Finnish national registries after reaching the primary end-point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating cell-free DNA</measure>
    <time_frame>At enrollment and at occurrence of castration resistance, assessed up to 60 months</time_frame>
    <description>Occurrence of adverse tumor traits predicting development of castration resistance in circulating cell free DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months</time_frame>
    <description>To see how ADT affects glucose tolerance and whether atorvastatin intervention has any effect on it</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular events during ADT</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months</time_frame>
    <description>Any cardiovascular events as described by the participant or evident from the patient files during the course of follow-up. Followed via national registries after meeting the primary end-point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life (QOL)</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 12 month intervals up to 60 months</time_frame>
    <description>Score from validated QOL questionnaire EORTC QLQ-C30 (range 0-100, with 100 denoting highest quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific quality of life (QOL)</measure>
    <time_frame>From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 12 month intervals up to 60 months</time_frame>
    <description>Score from validated QOL questionnaire EORTC QLQ-PR25 (range 0-100, with 100 denoting highest quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of atorvastatin. Daily dose of 80 mg for max. 5 years or until development of castration resistance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 5 years or until development of castration resistance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Capsules including 80 mg of atorvastatin</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Similar capsules as in the atorvastatin arm, but without the active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed metastatic (radiologically confirmed bone or soft tissue&#xD;
             metastasis or enlarged lymph nodes at minimum 15 mm in diameter beyond the pelvic&#xD;
             lymph nodes) or recurrent (requiring treatment after curative-intent surgery or&#xD;
             radiotherapy) adenocarcinoma of the prostate for which androgen deprivation or&#xD;
             antiandrogen therapy (GnRH agonist/antagonist, bicalutamide/flutamide, surgical&#xD;
             castration or enzalutamide/abiraterone monotherapy) is initiated as definitive&#xD;
             treatment no longer than 3 months before recruitment&#xD;
&#xD;
               -  previous prostatectomy and radiation therapy allowed&#xD;
&#xD;
               -  ADT/antiandrogen therapy for neoadjuvant hormone therapy is not included&#xD;
&#xD;
          -  Willingness to participate and signing of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Statin use at the time of recruitment or within 6 months of it&#xD;
&#xD;
          -  Previous adverse effects during statin therapy&#xD;
&#xD;
          -  Familial hypercholesterolemia or very high total cholesterol (9.3 mmol/l or above)&#xD;
&#xD;
          -  Clinically significant renal insufficiency (serum creatinine above 170 µmol/l) or&#xD;
             liver insufficiency (serum alanine aminotransferase more than 2x above the upper limit&#xD;
             of normal range)&#xD;
&#xD;
          -  Use of drugs that may interact with statins (St John's Wort, HIV protease inhibitors,&#xD;
             ciclosporin, macrolide antibiotics, fucidic acid, phenytoin, carbamazepine,&#xD;
             dronedarone or oral antifungal medication).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teemu Murtola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otto Ettala, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heikki Seikkula</last_name>
    <role>Study Director</role>
    <affiliation>Central Finland Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teemu Murtola, MD, PhD</last_name>
    <phone>+358-3 311 65015</phone>
    <email>teemu.murtola@uta.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aino Siltari, PhD</last_name>
    <email>aino.siltari@helsinki.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikkel Fode, MD, PhD</last_name>
      <email>mikkelfode@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter Oestergren, MD, PhD</last_name>
      <email>peter.busch.oestergren@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andres Kotsar, MD, PhD</last_name>
      <email>andres.kotsar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Department of Urology</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antti Rannikko, MD,PhD</last_name>
      <email>antti.rannikko@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Finland central hospital</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heikki Seikkula, MD, PhD</last_name>
      <email>heikki.seikkula@ksshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital, Department of Urology</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arto Salonen, MD,PhD</last_name>
      <email>arto.salonen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital, Department of Surgery</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teemu Murtola, MD,PhD</last_name>
      <email>teemu.murtola@epshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teemu Murtola, MD, PhD</last_name>
      <email>teemu.murtola@tuni.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otto Ettala, MD, PhD</last_name>
      <email>otto.ettala@utu.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Teemu Murtola</investigator_full_name>
    <investigator_title>MD, PhD, professor</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Castration resistance</keyword>
  <keyword>Cholesterol lowering drug</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Survival</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of individual-level data is not allowed by ethics board</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

